RE:RE:RE:RE:RE:RE:Get ready for more merger mania in the pharma sector We are entering a time where M&A's are a "different animal" and are no longer based on share price as we are seeing with the USD$ 2 Billion acquisitions of start-up companies and USD$5 Billion acquistions of pre-clinical companies.
The time where partnership & licensing agreements led up to a company's acquistion are a thing of the past given that Big Pharma is faced with a looming patent cliff and they need to commit themselves in a more substantial way with the outright acquisition of companies.
Simply stated ... "dancing around " around partnership and licensing deals today is a bad business development tactic and strategy for ONCY when Big Pharma is actively hunting for new and innovative assets to bolster and enhance their threatened piplelines, as Pfizer is today.
So once again - “Pfizer’s move put boards across big pharma on notice that if you’re not in the market buying these companies while they’re cheap, your competitors will,” Thomas Hayes, chairman and managing member of Great Hill Capital in New York, said.
Pfizer is saying to Big Pharma ... It's "either fish ... or cut bait" time and ONCY should heed this advice in negotiating an outright acquisition of the company.